Bristol-Myers Squibb Company ( (BMY) ) has released its Q1 earnings. Here is a breakdown of the information Bristol-Myers Squibb Company presented to its investors.
Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases, primarily operating in the pharmaceutical industry.
In the first quarter of 2025, Bristol Myers Squibb reported revenues of $11.2 billion, a 6% decrease from the previous year, but highlighted a strong performance in its Growth Portfolio, which saw a 16% increase in revenues. The company also raised its revenue guidance for the year, reflecting confidence in its strategic initiatives.
Key financial metrics for the quarter included a GAAP EPS of $1.20 and a non-GAAP EPS of $1.80. The Growth Portfolio’s revenue growth was driven by successful product launches and strategic initiatives, while the Legacy Portfolio faced declines due to generic competition and changes in U.S. Medicare Part D. The company also reported significant reductions in selling, general, and administrative expenses, as well as research and development costs, contributing to improved profitability.
Despite the overall revenue decline, Bristol Myers Squibb’s strategic focus on its Growth Portfolio and pipeline advancements positions it for future growth. The company is increasing its 2025 revenue guidance to a range of $45.8 billion to $46.8 billion and expects non-GAAP EPS to be between $6.70 and $7.00, indicating a positive outlook.
Looking ahead, Bristol Myers Squibb remains committed to advancing its multi-year plan to enhance agility and efficiency, with a clear strategy to deliver transformational medicines and achieve long-term growth.